Gsk (GSK) Current Assets (2009 - 2026)
Gsk (GSK) posted quarterly Current Assets of $23.6 billion for Q2 2026, little changed year-over-year from $23.6 billion in Q2 2025, and down 1.61% quarter-over-quarter from $23.9 billion in Q1 2026.
Gsk (GSK) Current Assets (2009 - 2026) Analysis & Trends
Gsk's Current Assets history runs 18 years deep, the most recent figure standing at $23.6 billion for Q2 2026.
- In Q2 2026, Current Assets changed 0.08% year-over-year to $23.6 billion; the TTM figure through Jun 2026 stood at $23.6 billion (changed 0.08% YoY), while the FY2025 annual figure was $23.1 billion, up 6.26% from the prior year.
- Current Assets for Q2 2026 stood at $23.6 billion, down from $23.9 billion in the prior quarter.
- The five-year high for Current Assets was $68.2 billion in Q2 2022, with the low at $20.5 billion in Q1 2022.
- The 5-year median for Current Assets is $23.6 billion (2025), against an average of $25.8 billion.
- The sharpest annual moves came in 2022 and 2023: Current Assets jumped 177.93% in 2022, then slumped 64.52% in 2023.
- Gsk's Current Assets stood at $24.4 billion in 2022, then fell by 5.01% to $23.1 billion in 2023, then declined by 5.72% to $21.8 billion in 2024, then climbed by 6.76% to $23.3 billion in 2025, then rose by 1.15% to $23.6 billion in 2026.
- Business Quant data shows GSK's Current Assets at $23.6 billion in Q2 2026, $23.9 billion in Q1 2026, and $23.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 36.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.56 Bn |
| Mar 31, 2026 | 23.94 Bn |
| Dec 31, 2025 | 23.29 Bn |
| Sep 30, 2025 | 24.08 Bn |
| Jun 30, 2025 | 23.58 Bn |
| Mar 31, 2025 | 22.78 Bn |
| Dec 31, 2024 | 21.82 Bn |
| Sep 30, 2024 | 22.48 Bn |
| Jun 30, 2024 | 21.16 Bn |
| Mar 31, 2024 | 21.82 Bn |
| Dec 31, 2023 | 23.14 Bn |
| Sep 30, 2023 | 26.90 Bn |
| Jun 30, 2023 | 24.21 Bn |
| Mar 31, 2023 | 23.97 Bn |
| Dec 31, 2022 | 24.36 Bn |
| Sep 30, 2022 | 23.86 Bn |
| Jun 30, 2022 | 68.24 Bn |
| Mar 31, 2022 | 20.53 Bn |
| Dec 31, 2021 | 25.17 Bn |
| Sep 30, 2021 | 25.16 Bn |